BRIEF-Palvella Therapeutics To Expand Phase 3 Selva Clinical Trial Of Qtorin™ 3.9% Rapamycin Anhydrous Gel (Qtorin™ Rapamycin)

Reuters

10 Feb

BRIEF-<a href="https://laohu8.com/S/PVLA">Palvella Therapeutics</a> To Expand Phase 3 Selva Clinical Trial Of Qtorin™ 3.9% Rapamycin Anhydrous Gel (Qtorin™ Rapamycin)

Feb 10 (Reuters) - Palvella Therapeutics PVLA.O:

PALVELLA THERAPEUTICS TO EXPAND PHASE 3 SELVA CLINICAL TRIAL OF QTORIN™ 3.9% RAPAMYCIN ANHYDROUS GEL (QTORIN™ RAPAMYCIN) FOR THE TREATMENT OF MICROCYSTIC LYMPHATIC MALFORMATIONS TO INCLUDE THE YOUNGER PEDIATRIC POPULATION, CHILDREN 3 TO 5 YEARS OLD
PALVELLA THERAPEUTICS INC - TO REPORT PHASE 3 TRIAL RESULTS IN Q1 2026

Source text: ID:nGNX6B2g7s

Further company coverage: PVLA.O

((Reuters.Briefs@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2510854433"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2510854433\",edition:\"fundamental\",,,undefined,":{"share":"https://ttm.financial/m/news/2510854433?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-02-10 21:10","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2510854433","market":"us","top_or_hot":-1,"title":"BRIEF-Palvella Therapeutics To Expand Phase 3 Selva Clinical Trial Of Qtorin™ 3.9% Rapamycin Anhydrous Gel (Qtorin™ Rapamycin)","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-<a href=\"https://laohu8.com/S/PVLA\">Palvella Therapeutics</a> To Expand Phase 3 Selva Clinical Trial Of Qtorin™ 3.9% Rapamycin Anhydrous Gel (Qtorin™ Rapamycin) </title></head><body><p><span>Feb 10 (Reuters)</span><span> - </span>Palvella <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> <span>PVLA.O</span>:</p><ul><li><p>PALVELLA THERAPEUTICS TO EXPAND PHASE 3 SELVA CLINICAL TRIAL OF QTORIN™ 3.9% RAPAMYCIN ANHYDROUS GEL (QTORIN™ RAPAMYCIN) FOR THE TREATMENT OF MICROCYSTIC LYMPHATIC MALFORMATIONS TO INCLUDE THE YOUNGER PEDIATRIC POPULATION, CHILDREN 3 TO 5 YEARS OLD</p></li><li><p>PALVELLA THERAPEUTICS INC - TO REPORT PHASE 3 TRIAL RESULTS IN Q1 2026</p></li></ul><p>Source text: <span>ID:nGNX6B2g7s</span></p><p>Further company coverage: <span>PVLA.O</span></p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BRIEF-Palvella Therapeutics To Expand Phase 3 Selva Clinical Trial Of Qtorin™ 3.9% Rapamycin Anhydrous Gel (Qtorin™ Rapamycin)</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBRIEF-Palvella Therapeutics To Expand Phase 3 Selva Clinical Trial Of Qtorin™ 3.9% Rapamycin Anhydrous Gel (Qtorin™ Rapamycin)\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-02-10 21:10</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-<a href=\"https://laohu8.com/S/PVLA\">Palvella Therapeutics</a> To Expand Phase 3 Selva Clinical Trial Of Qtorin™ 3.9% Rapamycin Anhydrous Gel (Qtorin™ Rapamycin) </title></head><body><p><span>Feb 10 (Reuters)</span><span> - </span>Palvella <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> <span>PVLA.O</span>:</p><ul><li><p>PALVELLA THERAPEUTICS TO EXPAND PHASE 3 SELVA CLINICAL TRIAL OF QTORIN™ 3.9% RAPAMYCIN ANHYDROUS GEL (QTORIN™ RAPAMYCIN) FOR THE TREATMENT OF MICROCYSTIC LYMPHATIC MALFORMATIONS TO INCLUDE THE YOUNGER PEDIATRIC POPULATION, CHILDREN 3 TO 5 YEARS OLD</p></li><li><p>PALVELLA THERAPEUTICS INC - TO REPORT PHASE 3 TRIAL RESULTS IN Q1 2026</p></li></ul><p>Source text: <span>ID:nGNX6B2g7s</span></p><p>Further company coverage: <span>PVLA.O</span></p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250210:nTUA1D6KNY:1","article_id":"2510854433","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2510854433","pubTimestamp":1739193002,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"BRIEF-Palvella Therapeutics To Expand Phase 3 Selva Clinical Trial Of Qtorin 3.9% Rapamycin Anhydrous Gel (Qtorin Rapamycin) Feb 10 (Reuters) - Palvella Therapeutics PVLA.O:PALVELLA THERAPEUTICS TO EX","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","PVLA":"Palvella Therapeutics"},"translate_title":"简报-Palvella Therapeutics将扩大Qtorin™3.9%雷帕霉素无水凝胶（Qtorin™雷帕霉素）的3期Selva临床试验","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"PVLA":0.9},"content_text":"BRIEF-Palvella Therapeutics To Expand Phase 3 Selva Clinical Trial Of Qtorin™ 3.9% Rapamycin Anhydrous Gel (Qtorin™ Rapamycin) Feb 10 (Reuters) - Palvella Therapeutics PVLA.O:PALVELLA THERAPEUTICS TO EXPAND PHASE 3 SELVA CLINICAL TRIAL OF QTORIN™ 3.9% RAPAMYCIN ANHYDROUS GEL (QTORIN™ RAPAMYCIN) FOR THE TREATMENT OF MICROCYSTIC LYMPHATIC MALFORMATIONS TO INCLUDE THE YOUNGER PEDIATRIC POPULATION, CHILDREN 3 TO 5 YEARS OLDPALVELLA THERAPEUTICS INC - TO REPORT PHASE 3 TRIAL RESULTS IN Q1 2026Source text: ID:nGNX6B2g7sFurther company coverage: PVLA.O ((Reuters.Briefs@thomsonreuters.com;))","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1}}}